Audited standalone and consolidated financial results for the quarter and financial year ended March. 31, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Astal Laboratories reported FY26 standalone revenue of Rs 15,678.68 lakhs, a massive jump from Rs 6,495.61 lakhs in FY25, driven by a change in business activity after the company's name change from Macro International. However, standalone profit before tax declined to Rs 1,086.56 lakhs from Rs 1,197.75 lakhs. On a consolidated basis, revenue was significantly higher at Rs 24,934.88 lakhs with PBT of Rs 1,773.03 lakhs, up 48% from Rs 1,197.75 lakhs. The auditors issued an unmodified (clean) opinion. Key concerns include negative operating cash flows of Rs -1,759.88 lakhs (consolidated), massive increase in trade receivables to Rs 7,475.98 lakhs from Rs 173 lakhs, and trade payables at Rs 12,380.47 lakhs, suggesting significant working capital stress despite strong revenue growth.
The stock shows exceptional revenue growth likely due to business transformation, but declining standalone profitability and negative operating cash flows raise concerns about the quality of earnings. Shareholders should monitor working capital management closely.